Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, raised $72 million on Wednesday by offering 5.5 million shares at $13, below the range of $14 to $16. This gives the company a market cap of $355 million, 13.6% below the initial terms, and an enterprise value of $212 million. Insiders plan to buy up to $35 million of the deal.
Dimension Therapeutics plans to list on the Nasdaq under the symbol DMTX. Goldman Sachs and Citi acted as lead managers on the deal.
